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Rhinoviruses are the major trigger of acute asthma exacerbations and asthmatic subjects are 
more susceptible to these infections. To investigate the underlying mechanisms of this increased 
susceptibility, we examined virus replication and innate responses to rhinovirus (RV)-16 
infection of primary bronchial epithelial cells from asthmatic and healthy control subjects.
Viral RNA expression and late virus release into supernatant was increased 50- and 7-fold, 
respectively in asthmatic cells compared with healthy controls. Virus infection induced late 
cell lysis in asthmatic cells but not in normal cells. Examination of the early cellular response 
to infection revealed impairment of virus induced caspase 3/7 activity and of apoptotic 
responses in the asthmatic cultures. Inhibition of apoptosis in normal cultures resulted in 
enhanced viral yield, comparable to that seen in infected asthmatic cultures. Examination of 
early innate immune responses revealed profound impairment of virus-induced interferon-
 
 
 
 
mRNA expression in asthmatic cultures and they produced 
 
 
 
2.5 times less interferon-
 
 
 
 
protein. In infected asthmatic cells, exogenous interferon-
 
 
 
 induced apoptosis and reduced 
virus replication, demonstrating a causal link between deficient interferon-
 
 
 
, impaired 
apoptosis and increased virus replication. These data suggest a novel use for type I interferons 
in the treatment or prevention of virus-induced asthma exacerbations.
 
Viral respiratory tract infections are responsible
for up to 85% of asthma exacerbations (1, 2),
with the most severe requiring hospitalization
(3). These infections can trigger severe asthma
exacerbations even when there is good asthma
control by compliant patients taking optimal
doses of inhaled corticosteroids (ICSs; 4, 5).
The most common pathogens associated
with asthma exacerbations are rhinoviruses
(RVs), which lead to increased lower airway
inflammation (6) and increased bronchial re-
sponsiveness (7). Subjects with asthma have in-
creased susceptibility to RV infection with
more severe lower respiratory tract symptoms
and reductions in lung function than normal
subjects similarly infected (8). Although RV
infects bronchial epithelial cells (BECs; 9) and
has been detected in the lower airways (9, 10),
the reasons why the asthmatic lower respira-
tory tract is more susceptible to the effects of
infection with RV are unknown.
Rapid induction of apoptosis in virus-
infected host cells is a critical component of in-
nate antiviral responses (11), as early apoptosis
prevents establishment of viral replication and
promotes phagocytosis of infected cells. Type I
IFNs are also an important component of the
innate immune response, having a direct anti-
viral effect on infected and neighboring cells,
while promoting acquired antiviral immune
responses (12). Recently they have been linked
to apoptotic responses to virus infections in
antiviral defense (11). Thus, type 1 IFNs play
critical roles in regulating apoptosis, as well as
innate and acquired immune responses in anti-
viral defense. Therefore we hypothesized
that asthmatic BECs have abnormal innate
responses to virus infection characterized by
impaired type 1 IFN production and impaired
virus-induced apoptosis resulting in increased
virus replication.
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To address this hypothesis we investigated virus replica-
tion, type 1 IFN production and apoptotic responses in pri-
mary BECs from asthmatic and normal subjects. We initially
studied cells from asthmatic subjects treated with ICSs, as the
great majority of asthmatics are on regular prophylactic ther-
apy with these agents. However, to determine whether ICSs
therapy influenced our observations, we also studied cells
from milder asthmatics completely naive to ICSs therapy.
 
RESULTS
ICAM-1 expression and induction with infection
 
Primary BECs from 14 subjects with moderately severe
asthma treated with ICSs and 10 normal healthy controls
were studied (Table I). As the cellular receptor for RV-16 is
ICAM-1 (13), we first determined whether surface ICAM-1
expression differed between asthmatic and normal BECs.
Before infection ICAM-1 expression was not significantly
different between subject groups (Fig. 1 A). By 24 h after in-
fection, ICAM-1 surface protein expression was significantly
induced in a virus-specific manner, consistent with previous
studies using primary BECs (14; Fig. 1 B), however, levels
were significantly greater in the normal cultures compared
with expression in the asthmatic cultures (Fig. 1 B). RV-16
infection also provoked a vigorous inflammatory response in
BECs from both asthmatic and healthy controls. There was a
significant induction of RANTES and IL-6 protein release at
48 h after infection (Fig. 1, C and D). There were no signif-
icant differences between the two groups, suggesting com-
parable levels of proinflammatory responses in cultures from
either group. UV-inactivated RV did not trigger a proin-
flammatory response.
 
Viral replication after epithelial cell infection and epithelial 
cell lysis
 
We next investigated whether primary BECs from asthmatic
subjects were more susceptible to increased viral replication
by determining levels of RV-16 vRNA expression 8 h after
infection. We observed significantly increased vRNA ex-
pression (by 
 
 
 
50-fold) in primary BECs from asthmatic
compared with normal subjects (Fig. 2 A). This was accom-
panied by a progressive increase in cell lysis in virus infected
BECs from asthmatic subjects, reaching a significant 3.4-fold
increase above baseline at 48 h. In contrast, there was no sig-
nificant induction of cell lysis in cells from normal subjects
either at 24 or 48 h after infection (Fig. 2 B), indicating that
the innate responses of these cells were sufficiently robust to
protect them from substantial lytic cell death. The increase
in lactate dehydrogenase (LDH)
 
 
 
activity was significantly
greater in asthmatic cells compared with the normal cells at
48 h (Fig. 2 C) and was specific to viral replication as there
was no significant increase in LDH activity in asthmatic cells
treated with medium alone or with UV inactivated RV-16
48 h after infection (Fig. 2 C).
Having observed that RV infection of asthmatic primary
BECs resulted in increased vRNA production and cell lysis,
we examined whether increased intact virus particles were
released into the supernatants. Recovery of viable RV was
significantly increased at 24 h and, by 48 h the virus release
was more than sevenfold greater in asthmatic compared with
normal primary BECs (Fig. 2 D). These results confirmed a
link between early vRNA production, later cell lysis and vi-
rus release and all were significantly increased in asthmatic
primary BECs. The normal cells were protected against lytic
virus replication, with 50 times lower levels of vRNA pro-
duction, no significant cell lysis and release of almost eight
times less new virus progeny. These data suggested that post-
binding events early in the replication cycle were profoundly
influencing early viral RNA production, later cell lysis and
virus release from infected cells.
 
Bronchial epithelial cell viability and induction of caspases 
after RV infection
 
As apoptosis is a natural defense that protects against virus
replication, our findings of increased replication in asthmatic
cells led us to investigate whether early apoptotic responses
were different between subject groups. There was a signifi-
cant reduction in viable annexin-V (AxV
 
 
 
)/7-amino-acti-
nomycin (7AAD
 
 
 
) cell numbers 8 h after RV-16 infection
of normal BECs, such that only 63% of cells were viable and
available for virus replication at this time point. This was not
observed in cells treated with medium alone or UV-inacti-
vated RV-16 (Fig. 3 A). Similarly, infection of asthmatic
BECs with RV-16 also significantly reduced numbers of
viable cells 8 h after infection and this was also dependent on
virus replication (Fig. 3 A). However the reduction in viable
cells was of a significantly lesser magnitude with 80% of cells
 
Table I.
 
Subject characteristics
 
Asthma (ICSs treated) Asthma (ICSs naive) Healthy controls p-value
 
Number 14 10 10 NA
Sex (percent male) 69% 60% 60% P 
 
  
 
0.8
Mean age (range) 32 (21–58) 32 (12.6) 29 (24–38) P 
 
  
 
0.4
Mean FEV
 
1%
 
 predicted (SD) 77.3
 
a
 
 (15.5) 103.6 (9.8) 110.3 (13.6) P 
 
 
 
 0.001
Mean dose of ICSs, BDP 
 
 
 
g/day (SD) 490 (260) 0 0 NA
 
FEV
 
1%
 
 predicted refers to the forced expiratory volume in 1 s expressed as a percentage of the predicted value.
ICSs refers to ICSs. Dose is expressed in dose of beclomethasone dipropionate (BDP) in 
 
 
 
g per day where 1 
 
 
 
g BDP 
 
  
 
1
 
  
 
g Budesonide or 0.5 
 
 
 
g Fluticasone.
 
a
 
Significantly lower than healthy controls, P 
 
  
 
0.001. 
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remaining viable and available for virus replication (Fig. 3
A). By analyzing changes in frequencies of apoptotic cells
and necrotic cells over the first 8 h after RV-16 infection,
we found that there was a significant increase in apoptotic
normal BECs, which was not observed in cells treated with
medium alone or UV-inactivated RV-16 confirming that
induction of apoptosis was directly related to virus replication
(Fig. 3 B). Infection of asthmatic BECs with RV-16 also sig-
nificantly increased numbers of apoptotic cells at 8 h after in-
fection (Fig. 3 B), however, the increased apoptotic cells
(therefore not available for virus replication) in asthmatic BECs
(1.4-fold increase from baseline), was significantly less than
that observed in healthy control BECs (2.2-fold; Fig. 3 B),
confirming impairment of apoptotic responses in asthmatic
cells. There were no significant differences between subject
groups in the number of necrotic cells at 8 h after virus in-
fection (unpublished data), confirming that alterations in
early cell viability were a result of increased apoptosis, not
early necrosis.
To investigate whether RV-induced apoptosis involved
the activation of caspase 3/7, we next determined levels of
activated caspase 3/7. There was significant induction of
Figure 1. ICAM-1 expression of normal and asthmatic BECs before 
and after RV infection. (A and B) ICAM-1 expression was measured by 
flow cytometry immediately before RV-16 infection (A) or 24 h after 
infection (B). Data are expressed as mean fluorescence intensity (MFI). 
Before infection, asthmatic cells had a tendency to a lower median MFI 31 
IQR (12, 80) compared with healthy control cells 67 (34, 83) but this was 
not significant (P   0.4; A). ICAM-1 was significantly induced in both 
asthmatic and healthy control cells by 24 h (B), asthmatic cells had an 
MFI of 54.6 (27.6, 145.2) healthy control cells 110.4 (65, 195.3; P   0.3). 
In these and all later box whisker plots, the line inside the box represents 
the median, upper box border represents 75th quartile, lower 25th quartile, 
whiskers are 5th and 95th centiles, dots represent outliers. (C and D) IL-6 
and RANTES production was measured 48 h after infection in the super-
natant of cells by ELISA. In C there was virus-specific release of IL-6 from 
RV infected in asthmatic cells with a median fold increase from baseline of 
14 (IQR 5.2, 19.8) and in healthy control cells of 4 (4, 22.4). This was signif-
icantly greater than in cells treated with medium alone or UV-inactivated 
RV (P   0.01), but there was no difference between the groups. In D there 
was virus-specific release of RANTES from RV infected in asthmatic cells 
with a median fold increase from baseline of 66 (IQR 33.2, 125.8) and in 
healthy control cells of 82.3 (25.2, 215.9). This was significantly greater 
than in cells treated with medium alone or UV-inactivated RV (P   0.01), 
but there was no difference between the groups. *, Significantly different 
from cells treated with medium alone and UV-inactivated RV-16, P   0.05. 
Shaded bars, asthma; open bars, healthy controls. 
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caspase 3/7 activity in healthy control cells at 4 h, peaking at
8 h and still elevated 12 h after infection. Induction of
caspase 3/7 activity in normal cells was significantly greater
than that seen in asthmatic cells (Fig. 3 C). These data dem-
onstrate that RV-induced apoptosis occurs via the caspase 3/7
pathway and that activation of this pathway is defective in
asthmatic subjects.
To confirm whether increased virus production by asth-
matic BECs is a direct consequence of an impaired apoptotic
response, we then treated cells with the caspase 3 inhibitor
ZVD-fmk, before and after infection with RV-16. Caspase 3
inhibition impaired RV-induced apoptosis in the normal
cultures but had no significant effect on asthmatic cells com-
pared with infection alone (Fig. 4 A). Treatment of the nor-
mal BECs with ZVD-fmk also had a direct impact on RV-16
production with a significant 
 
 
 
4.5-fold increase in RV titer
at 48 h compared with those infected with RV-16 alone
(Fig. 4 B). Consistent with the fact that there was no signifi-
cant inhibition of apoptosis in asthmatic cells treated with
ZVD-fmk, we observed no significant increase in virus title
(Fig. 4 B). These data provide direct evidence that inhibition
of early apoptotic responses to viral infection is associated
Figure 2. RV-16 replication and release from normal and asthmatic 
BECs. (A) RV-16 vRNA production was measured by qPCR after 8 h of 
infection. Median (IQR) production ( 106) from asthmatic cells was 
significantly increased at 2.1 (0.16, 9.7) compared with 0.04 (0.009, 0.06) 
from healthy controls (P   0.007). (B and C) Late cell lysis as a consequence 
of RV-16 infection was determined by analysis of LDH activity in culture 
supernatants; values represent the fold induction from baseline. Data points 
represent the mean and the SD. In asthmatic cells LDH activity progres-
sively increased over time and was significantly increased from baseline at 
both 24 h (P   0.01) and 48 h (P   0.003) whereas in healthy control cells 
there was no significant increase even at 48 h (P   0.2; B). By 48 h, the 
mean LDH activity from asthmatic cells was significantly greater than in 
normal cells, at 3.4 (0.1)-fold increased over baseline compared with only 
a 1.34 (0.1)-fold increase in the healthy control cells (P   0.0001; C). 
Induction of LDH activity was shown to be virus replication dependent in 
that no significant change in LDH activity was seen in cells treated with 
medium alone or UV-inactivated RV (C). (D) RV-16 release into the super-
natant of infected cells was determined by calculating the TCID50   104/ml 
by titration assay in Ohio HeLa cells. The supernatant from 14 ICSs requir-
ing asthmatics and 10 healthy controls were examined on individual titra-
tion plates. Data points represent the mean and the standard deviation. By 
48 h significantly more RV was detected from asthmatic cells with a mean 
TCID50   104/ml of 3.99 (0.8), compared with 0.54 (0.12) in healthy control 
cells (P   0.001). *, Significantly different from cells treated with UV inac-
tivated RV or medium alone. **, Results from asthmatic cells and healthy 
controls significantly different (P   0.01).  , Significantly increased above 
baseline (P   0.001). Shaded bars, asthma; open bars, healthy controls. 
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with increased later virus release and that inhibition of apop-
tosis in normal cells results in a phenotype typical of asth-
matic cells (that is impaired apoptosis and increased virus
replication). Notably, inhibition of apoptosis in normal cells
was sufficient to increase virus replication to levels similar to
those observed in the asthmatic cells.
 
Release of interferon-
 
 
 
 from BECs after infection
 
Because IFN-
 
 
 
/
 
 
 
 has recently been shown to induce apop-
totic responses in antiviral immunity (11), and because IFN-
 
 
 
is known to be secreted first and to strongly induce the
IFN-
 
 
 
 subfamily (15), we investigated whether impaired
production of IFN-
 
 
 
 was the underlying mechanism regu-
lating the abnormal antiviral response in asthmatic cells. RV
infection induced a robust almost fourfold increase in IFN-
 
 
 
mRNA expression in healthy control BECs 8 h after RV-16
infection, significantly greater than both medium and UV-
inactivated virus controls, confirming the induction to be
live-virus specific (Fig. 5 A). In marked contrast, a similar
increase in IFN-
 
 
 
 mRNA expression in response to RV in-
fection at 8 h was absent in asthmatic cells (Fig. 5 A). Im-
paired induction of IFN-
 
 
 
 mRNA expression by RV-
infected asthmatic BECs was also reflected by impaired
protein production with IFN-
 
 
 
 protein levels being more
than twofold higher in supernatants from healthy control
cells compared with those from asthmatic cells (Fig. 5 B).
Confirming the relationships between IFN-
 
 
 
 production
and apoptosis, and between apoptosis and suppression of vi-
rus replication, there was a positive correlation between in-
duction of apoptosis at 8 h and induction of IFN-
 
 
 
 mRNA
at 8 h, r 
 
 
 
 0.43 (P 
 
 
 
 0.04) and an even stronger negative
correlation between IFN-
 
 
 
 release and virus release at 48h
(TCID
 
50
 
 
 
  
 
10
 
4
 
/ml), r 
 
 
 
 
 
 
 
0.79 (P 
 
 
 
 0.01). These data
confirmed that IFN-
 
 
 
 induction by RV infection of pri-
mary BECs from asthmatic subjects is profoundly impaired
and this impairment is related to impaired apoptosis and in-
creased viral replication.
To examine whether these findings might be related to
differences in ICAM-1 expression levels, or were confined to
a major group RV, experiments were performed using BECs
 
Figure 3. Differences in cell viability and apoptotic response after 
RV-16 infection in asthmatic and normal BECs.
 
 (A) Viable (AxV
 
 
 
/7AAD
 
 
 
) 
cell number was determined 8 h after infection and expressed as percent 
viability compared with cells treated with medium alone. Infection with 
RV-16 led to a significant reduction in median (IQR) cell viability in both 
asthmatic and control cells compared with both medium alone (P 
 
  
 
0.03 
and 0.02, respectively) and UV-inactivated RV-16 (P 
 
  
 
0.02 and 0.001, 
respectively). In asthmatic cells there was significantly better viability, 
median 80% (74, 86), compared with healthy controls 63% (51, 69; P 
 
  
 
0.02). 
(B) Apoptotic (AxV
 
 
 
/7AAD
 
 
 
) cells were also analyzed 8 h after RV-16 
infection. Data are expressed as median (IQR) fold change in apoptosis 
from baseline. There was a significant and virus-specific increase in cell 
apoptosis in response to infection in cells from both groups, however, this 
response was significantly impaired in asthmatic cells with a fold increase 
of only 1.4 (1.3, 1.7), compared with 2.2 (2.1, 2.3) in healthy controls (P 
 
  
 
0.02). 
(C) The time course for activation of caspase 3/7 by RV-16 was determined 
in cells from 10 ICSs requiring asthmatics and 10 healthy controls, all con-
ditions were done in quadruplicate, values represent the fold induction 
from baseline. There was significant mean (SD) induction of active caspase 
3/7 in response to infection in normal cells at 4, 8, and 12 h, induction 
reached a plateau at 8 h. In asthmatic cells the induction was later, being 
significantly increased above baseline only at 8 and 12 h and was of sig-
nificantly reduced magnitude at each time point compared with normal 
cells. At 8 h there was a significantly impaired induction of active caspase 
3/7 in asthmatic cells (mean [SD] 
 
 
 
 1.47 [0.13]) compared with healthy 
controls (mean [SD] 
 
 
 
2.16 [0.34]; P 
 
  
 
0.004). *, Significantly different 
from cells treated with UV-inactivated RV-16 and medium only (P 
 
  
 
0.01). 
**, Asthmatic cells significantly different from healthy controls (P 
 
  
 
0.05). 
 
 
 
, Significantly different from baseline (P 
 
  
 
0.05). Shaded bars, asthma; 
open bars, healthy controls. 
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from eight asthmatic subjects and eight healthy controls,
which were infected with the minor group RV, RV-1B. In
this case, we also found evidence of early apoptosis in BECs
from healthy controls with a 2.3-fold increase (interquartile
range [IQR] 1.98, 2.43) at 8 h after infection, but this was
again impaired in BECs from asthmatic subjects where the
fold increase was only 1.32 (IQR 1.15, 1.4; P 
 
  
 
0.03). In ad-
dition, healthy control BECs demonstrated a vigorous IFN-
 
 
 
response at 48 h with median levels of 1,799 pg/ml (IQR
696, 3,402) compared with BECs from asthmatic donors,
which released 453 pg/ml (IQR 254, 886; P 
 
  
 
0.03).
 
The effect of interferon-
 
 
 
 on epithelial cell apoptosis in 
response to RV infection and treatment with poly(I)/poly(C)
 
To confirm that the impairment of IFN-
 
 
 
 production in
asthmatic cells was functionally related to impaired apop-
totic responses, we tested the ability of exogenous IFN-
 
 
 
to induce apoptosis in RV-16–infected asthmatic BECs
alone. To mimic the effects of IFN-
 
 
 
 during both initial
infection and the secondary wave of infection consequent
upon new virus released from neighboring infected cells,
we studied cells exposed to exogenous IFN-
 
 
 
 just after in-
fection or both before and after infection respectively. In
both cases (Fig. 5 C) treatment of cells with IFN-
 
  during
infection caused a doubling in the number of apoptotic
cells compared with treatment with IFN-  or virus alone,
neither of which caused significant increases in the fre-
quency of apoptotic cells. IFN-  was also capable of induc-
ing apoptosis in the presence of poly(I)/poly(C) (Fig. 5 C),
confirming that signals involving recognition of double
stranded RNA are sufficient for commitment to apoptosis
in response to IFN- .
The effect of exogenous interferon-  on recovery of RV 
from asthmatic BECs
Finally, we investigated whether reconstitution of type 1
IFN responses in asthmatic cells with exogenous IFN-  was
able to overcome the increased RV replication observed in
asthmatic primary BECs. In line with its ability to induce
apoptosis of virally infected asthmatic BEC, IFN-  caused a
significant reduction in RV-16 infectious virus release into
supernatants of asthmatic BECs (Fig. 5 D). The protection
afforded was greater when IFN-  was present both before
and after infection indicating that type 1 IFN production
during the initial phase of infection was likely critical in pre-
vention of the secondary wave of infection consequent upon
new virus released from neighboring infected cells.
The effect of corticosteroids on virus replication, cell 
viability, and interferon-  release
To determine whether the deficient innate antiviral responses
observed in the cells from subjects with moderately severe
asthma (who were all treated with ICSs) was related either to
asthma severity or to corticosteroid exposure, we next studied
a group of mild asthmatics that had never used inhaled or
parenteral corticosteroids (ICSs naive, Table I). In addition we
treated cells from ICSs naive asthmatic cells with dexametha-
sone at doses of 10 and 100 nM for 24 h before infection with
RV-16 and investigated their response in terms of interferon- 
and apoptotic responses to infection and virus replication.
Figure 4. Inhibition of caspase activity inhibits apoptosis and 
increases RV-16 replication. (A) The effect of inhibition of caspase-3 us-
ing the inhibitor, ZVD-fmk, was measured by flow cytometry. Cells were 
treated with RV-16 alone or with ZVD-fmk, before and after infection with 
RV-16. Results are expressed as the fold change in apoptotic cells compared 
with cells treated with medium alone. In asthmatic cells were there was a 
median (IQR) induction of apoptosis above baseline of 1.4 (1.3, 1.7) with 
RV-16 alone; pretreatment of cells with the ZVD-fmk, had little effect on 
apoptosis (median (IQR)   1.12 (1.01, 1.8); (P   0.4). However, in healthy 
controls cells, RV-16 infection resulted in a median (IQR) fold induction of 
apoptosis above baseline of 2.2 (2.1, 2.3) and this was abolished by pretreat-
ment with ZVD-fmk (median [IQR] 0.82 [0.76, 0.86; P   0.03]). (B) The effect 
of caspase-3 inhibition on RV-16 production was measured by HeLa titra-
tion assay on the BEC supernatant removed after 48 h of infection. There 
was no difference seen in the TCID50   104/ml in the supernatant removed 
from asthmatic cells infected with RV-16 (median [IQR]   3.56 [3.50–3.62]) 
compared with infected cells treated with ZVD-fmk (median [IQR]   3.5 
[3.45–3.62]; P   0.94). However, for healthy control BECs, the TCID50   104/ml 
increased greater than fourfold, from a median (IQR) value of 0.6 (0.4, 0.63) 
with infection alone to 2.78 (0.63, 6.32; P   0.01) in the presence of RV-16 
and ZVD-fmk. Shaded bars, asthma; open bars, healthy controls.JEM VOL. 201, March 21, 2005 943
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Figure 5. Impaired IFN-  production in asthma and its role in 
restoring apoptotic and antiviral response in asthmatic cells. (A) Induc-
tion of IFN-  mRNA was measured by qPCR after 8 h of RV-16 infection. 
There was no significant induction of IFN-  mRNA from asthmatic cells 8 h 
after infection with RV-16, median (IQR) fold induction from baseline control 
of 0.3 (0.3, 0.8), which was not significantly different from cells treated with 
medium alone or UV inactivated RV-16. In contrast there was a 3.6 (3.4, 3.6)-
fold increase in IFN-  mRNA expression in cells from healthy controls 
(P   0.004). (B) Release of IFN-  into culture supernatants 48 h after infec-
tion was measured by ELISA. For asthmatic BECs, median (IQR) IFN-  levels 
were significantly reduced at 721 (464, 1,290) pg/ml, compared with 1,854 
pg/ml (758, 3,766; P   0.03) in healthy controls. In both groups there was a 
significant increase above cells treated with medium alone and UV-inacti-
vated RV-16 (unpublished data). (C) The ability of IFN-  to restore induction 
of apoptosis in RV-16–infected asthmatic cells was measured by FACS anal-
ysis as described in the legend to Fig. 3. Asthmatic cells were either pretreated 
with IFN-  (100 IU) for 24 h or simultaneously exposed to RV-16 and IFN- . 
To mimic the presence of viral RNA, cells were also exposed to poly(I)/poly(C) 
a synthetic double-stranded RNA oligonucleotide, instead of RV-16. Results 
are expressed as the median (IQR) fold increase in apoptotic cells from base-
line at 8 h after infection. There was no significant increase in apoptosis in 
cells exposed to either IFN-  1.2 (1.1, 1.8; P   0.3), RV-16 1.7 (1.3, 1.9; P   0.2) 
or poly(I)/poly(C) 1.9 (1.7, 3.5; P   0.08) alone. In cells simultaneously 
treated with RV-16 and IFN-  there was a tendency to increased apoptosis 
3.8 (1.7, 5.0; P   0.11) whereas in those pretreated with IFN-  for 24 h and 
then infected there was a significant induction of apoptosis 5.6 (3.9, 5.7; 
P   0.02, compared with virus alone). In cells exposed to poly(I)/poly(C) 
alone there was a similar trend toward an increase in apoptosis 1.9 (1.7, 3.5; 
P   0.08) which was significantly enhanced by simultaneous treatment 
with IFN-  5.1 (3.9, 5.6; P   0.01) and further enhanced by 24 h pretreat-
ment with IFN-  9.3 (6.6, 9.3; P   0.001), compared with poly(I)/poly(C) alone. 
(D) The effect of IFN-  on virus release from asthmatic cells was measured 
by HeLa titration assay of asthmatic BEC culture supernatants removed 48 h 
after infection. Cells were either pretreated with IFN-  (100 IU) for 12 h and 
then exposed to RV-16 or were treated with IFN-  immediately after infec-
tion. There was a significant reduction in virus release in cells treated with 
IFN-  after infection median TCID50   104/ml 2.78 (2, 3.56; P   0.04) and 
a further reduction in cells pretreated with IFN-  1.12 (0.28, 1.34) com-
pared with cells infected with RV-16 alone 3.56 (3.5–3.62; P   0.012). 
*, Significantly different from medium alone. Shaded bars, asthma; open 
bars, healthy controls.A DEFICIENT INNATE IMMUNE RESPONSE IN ASTHMATIC EPITHELIUM TO RHINOVIRUS | Wark et al. 944
The release of IFN-  after RV-16 infection was just as
profoundly impaired in primary BECs from ICSs-naive
asthma as it was in cells from ICSs-treated asthma (Fig. 6 A).
In vitro pretreatment of cells from healthy controls and ICSs
naive subjects with dexamethasone (10 or 100 nM) had no
significant effect on RV-16–induced IFN-  (Fig. 6 A). Sim-
ilarly, RV-16 induction of apoptosis of BECs from ICSs na-
ive asthmatics was also just as profoundly impaired when
compared with cells from healthy controls and again treat-
ment with dexamethasone had no significant effect in or
ICSs-naive asthma (Fig. 6 B). In terms of virus replication,
cells from ICSs naive mild asthmatics were intermediately
susceptible to RV replication with virus titers exactly half
way between those observed in cells from ICSs requiring
moderate asthmatics and cells from normal controls (Fig. 6 C),
again there was no significant effect of pretreatment of
cells from healthy controls and ICSs naive asthmatics with
dexamethasone (Fig. 6 C).
Figure 6. The effect of corticosteroids on interferon-  release 
apoptotic responses and virus replication. The results from asthmatic 
cells (those requiring ICSs) and healthy controls were compared with asth-
matic subjects who had never used corticosteroids (ICSs naive). Cells from 
healthy controls and ICSs naive asthmatics were treated with RV-16 and 
pretreated for 24 h with dexamethasone (Dex) at 10 and 100 nM and then 
infected with RV-16. only the results from healthy control cells are displayed 
in the figures. (A) Release of IFN-  into culture supernatants 48 h after 
infection was measured by ELISA. As noted in asthmatic BECs, median (IQR) 
IFN-  levels were significantly reduced at 721 (464, 1,290) pg/ml, compared 
with 1,854 pg/ml (758, 3,766; P   0.01) in healthy controls. This was also 
seen in ICSs naive asthmatic cells 666 (387, 1,039) compared with healthy 
controls (P   0.02). The addition of Dex did significantly alter these levels. 
In healthy control cells; 10 nM 1717 (720, 1,990) compared with infected 
control cells (P   0.55) or 100 nM 990 (721, 2,656). This was also seen in 
ICSs-naive asthma; 10 nM 772 (581, 1,220) compared with ICSs-naive 
asthma cells infected alone (P   0.7), though at 100 nM; 449 (389, 609) 
there appeared to be a reduction, this did not reach statistical significance 
(P   0.2). (B) Apoptotic (AxV /7AAD ) cells were also analyzed 8 h after 
RV-16 infection. Data are expressed as median (IQR) fold change in apoptosis 
from baseline. Healthy controls cells had significantly more virus-specific 
apoptosis 2.19 (1.99, 2.2), compared with asthmatic cells (ICSs requiring) 1.39 
(1.35, 1.67; P   0.01) and ICSs naive asthmatic cells 1.36 (1.2, 1.5; P   0.004). 
The addition of Dex to healthy control cells had no significant impact on 
apoptosis compared with cells not pretreated, at either 10 nM 2.16 (1.86, 2.6; 
P   0.96) or 100 nM 1.87 (1.65, 2.14; P   0.09). This was also seen in ICSs-
naive asthma cells at 10nM 1.26 (1.2, 1.8) compared with ICSs naive cells 
infected alone (P   0.97) and 100 nM 1.16 (1.1, 1.4; P   0.08). (C) RV-16 
release into the supernatant of infected cells was determined by calculat-
ing the TCID50   104/ml by titration assay in Ohio HeLa cells. By 48 h
significantly more RV was detected from asthmatic cells with a mean
TCID50   104/ml of 3.99 (0.8), compared with 0.54 (0.12) in healthy control 
cells (P   0.002). There was a trend to higher titer in ICSs naive asthmatics 
2.2 (1.2), but this was not significantly different from either ICSs requiring 
asthmatics or healthy controls. The addition of dexamethasone 10 nM in 
control cells 0.46 (0.3) and ICSs-naive asthma cells 2.1 (1.3) or 100 nM in 
control cells 0.42 (0.3) and ICSs-naive asthma 2.1 (1.3) had no significant 
effect. Shaded bars, asthma (ICSs treated); hatched bars, asthma (ICSs naive); 
open bars, healthy controls.JEM VOL. 201, March 21, 2005 945
ARTICLE
DISCUSSION
Using in vitro–cultured primary BECs from asthmatic and nor-
mal volunteers, we have demonstrated that asthmatic cells have
an abnormal innate response to infection by RV-16, resulting
in increased virus replication and cell lysis compared with cells
from healthy normal controls. Asthmatic cells produced mark-
edly increased levels of viral RNA, released almost eight times
as many new virus progeny and infection led to progressive cell
lysis. A similar response was also observed in asthmatic BECs
exposed to the minor group RV, HRV-1B, which gains entry
into the cell via the very low density lipoprotein receptor (16).
This suggests that the observed response of asthmatic epithelial
cells is a function of altered intracellular signaling rather than
differences in ICAM expression and viral entry into the cells.
To explore the mechanisms behind this increased sus-
ceptibility of asthmatic epithelial cells to viral replication
and cytolysis, we studied innate antiviral defences in the
cells from both subject groups. Asthmatic cells were shown
to be resistant to early apoptosis after infection with RV-16
and to have a profoundly deficient type I interferon re-
sponse that was related to increased virus replication. These
findings are in contrast with previous studies in which we
demonstrated that asthmatic BECs are more susceptible to
oxidant induced apoptosis (17). Thus, even though other
stimuli can activate readily the apoptotic mechanism in
asthmatic epithelial cells, it is not triggered in response to
virus infection. The early apoptotic response in virally in-
fected normal cells was shown to be a key protective mech-
anism since inhibition of apoptosis in healthy control cells
led to enhanced virus release, comparable to levels observed
in asthmatic cells. A link between this and the actions of
IFN-  was demonstrated by the ability of exogenous IFN- 
to induce apoptosis in asthmatic cells infected with RV-16
and to reduce virus production to levels similar to those ob-
served in normal cells. We could find no evidence of infec-
tion with mycoplasma or other adventitious agents that
might provide an explanation for the low level of IFN- 
production by the asthmatic cell cultures. Furthermore,
based on the ability of exogenous IFN-  to induce apopto-
sis in the asthmatic epithelial cells infected with RV or
dsRNA, it seemed unlikely that there was deactivation of
downstream signaling pathways as a consequence of chronic
infection. A similar abnormal apoptotic and deficient inter-
feron-  response was seen in cells derived from ICSs naive
asthmatics and in vitro pretreatment of steroid naive cells
with dexamethasone had no significant effect upon IFN- 
production, apoptosis, or virus replication. Epidemiological
evidence demonstrates that asthmatic subjects develop more
severe lower respiratory symptoms and reductions in lung
function when infected with RV (8), however the mecha-
nisms behind this increased susceptibility to RV infection
were unknown. The data presented in this report indicate
that impaired type 1 interferon production is likely to be an
important mechanism.
It has been demonstrated previously that antiviral path-
ways are redundant, and that loss of one pathway does not
lead to increased susceptibility to virus infection. Although
we observed that production of IFN  from RV-16–infected
asthmatic epithelial cells was lower than normal, their proin-
flammatory responses to viral infection appeared to be intact,
as levels IL-6 and RANTES were similarly elevated in nor-
mal and asthmatic epithelial cell cultures. These findings are
similar to other studies in which we compared cytokine pro-
duction from normal and asthmatic BECs and failed to see
differences in IL-8 and GM-CSF production in response to
TNF , IL-4, IL-13, or house dust mite allergen, but found
lower TGF  production from asthmatic BECs under the
same conditions (18). Given that some of the antiviral re-
sponses remain intact in asthmatic BECs, it seems unlikely
that all antiviral pathways are defective, rather that the lesion
is selective for the pathway(s) that trigger expression of IFN- .
This abnormality is most likely to result in only a subtle im-
pairment of the immune response, making it more likely that
an inflammatory response will need to occur in the airways
to eliminate the infection.
The main role of type 1 IFNs, however, is in innate im-
munity, where they are critical regulators of a wide array of
innate protective responses. Interferon-  is induced first, it
then induces interferon- . Both induce a wide variety of an-
tiviral proteins; including RNases that digest viral double-
stranded RNA to limit viral replication. Interferon- /  also
induce the antiviral protein kinase (PKR), which limits viral
replication and induces apoptosis (19). Type I interferons
have also been shown to induce apoptosis via activation of
the tumor suppressor gene p53 in response to vesicular sto-
matitis virus infection in mice, further enhancing antiviral
activity (11) and demonstrating that early apoptosis is a key
protective innate immune antiviral response. We have con-
firmed this important role for type I interferons and apopto-
sis in relation to RV infection in human cells. The release of
type I interferons from infected cells not only reduces virus
spread from an infected cell to neighboring cells but also
causes surrounding cells to become primed to an antiviral
state with early apoptosis on exposure to virus. Infected apop-
totic cells would then be removed by phagocytosis, virus
replication minimized, and this would limit the magnitude
of inflammatory responses to infection.
Antiinflammatory treatment with ICSs improves airway
inflammation and symptoms associated with stable atopic
asthma, but does not influence airway inflammation associ-
ated with acute exacerbations precipitated by RV infection
(20) nor does it effectively prevent virus-induced exacerba-
tions (21). In addition, ICSs are recommended for mainte-
nance therapy for all forms of asthma except mild intermit-
tent asthma (22). Although it is possible that long-term
treatment of asthmatics with ICSs may have influenced the
phenotype of the cultured cells, it is unlikely that the ob-
served effects are a consequence of residual corticosteroid in
the cultures as cells were investigated at passage two after re-
peated changes of media and the observed proinflammatory
responses to RV-16 infection were normal. Nonetheless, to
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to infection in cells from a group of ICSs naive asthmatics
and studied the effect of in vitro treatment of these cells with
dexamethasone. These cells were intermediately susceptible
to virus replication, and they still demonstrated profoundly
impaired apoptotic and type 1 interferon responses. In vitro
treatment with dexamethasone at high doses was unable to
induce the impaired innate responses seen in the cells from
moderately severe asthmatics requiring ICSs. For these rea-
sons the in vitro data appear entirely consistent with clinical
observations already made (20). The similar response seen in
ICSs naive cells from mild asthma confirms that the deficient
innate responses and increased virus replication are not likely
due to corticosteroid therapy.
Peripheral blood monocytes taken from asthmatic sub-
jects and cultured with RV have a reduced interferon-  re-
sponse, suggesting asthmatics may have a deficient Th1-ac-
quired immune response to RV infection, though the
mechanism for this is unclear (23). Because type 1 interfer-
ons (IFN- / ) are known to promote antiviral acquired im-
mune responses (12), we suggest that deficient innate epithe-
lial IFN- /  response may be one mechanisms leading to a
deficient Th1-acquired immune response. In vivo studies
investigating both innate and acquired immune responses
will be required to confirm whether this is true.
Our results offer a logical explanation for asthmatic sub-
jects having lower respiratory tract symptoms and reductions
in lung function of greater severity and duration as a conse-
quence of RV infection (8). Although infection of BECs is
limited in nonasthmatic subjects by an innate antiviral re-
sponse and induction of apoptosis in infected cells, a defi-
ciency of IFN-  in asthma facilitates virus replication and
cytolysis with increased infection of neighboring cells. Exag-
gerated inflammatory responses are likely to result in asth-
matics in vivo, consequent upon the increased replication
and the cytolytic effects of the virus infection. Crucially, this
defect can be restored in vitro by provision of exogenous
IFN-  that restores apoptotic responses and limits virus rep-
lication to levels observed in normal cells. Thus, we propose
that IFN-  may have therapeutic utility in preventing or
treating virus-induced exacerbations of asthma.
MATERIALS AND METHODS
All subjects were nonsmokers, with no exacerbations or respiratory tract
infections in the preceding 4 wk. Allergy skin tests used a panel of com-
mon aeroallergens and were considered positive if the wheal response was
 3 mm than the negative control. Lung function was assessed by spirome-
try and bronchial hyperresponsiveness by histamine challenge. Asthma was
diagnosed in atopic individuals with a consistent history and evidence of
bronchial hyperresponsiveness (defined by a PC20 histamine  8 mg/ml)
and was categorized in accordance with the GINA guidelines (24). Sub-
jects with asthma were divided into those with moderate disease, who had
stable symptoms and used ICSs or had mild intermittent symptoms requir-
ing the use of bronchodilators but who had never used inhaled or
parenteral corticosteroids (Table I). Healthy controls had no previous his-
tory of lung disease, normal lung function, no evidence of bronchial hy-
perresponsiveness, and were nonatopic. The study was approved by the
Southampton University Hospital Ethics Committee. All subjects gave
written informed consent.
Bronchial epithelial cell tissue culture. Primary BECs were grown
from bronchial brushings ( 95% epithelial cells), which were obtained by
fiber-optic bronchoscopy in accordance with standard guidelines (25); there
was no significant difference in the proportion of columnar and basal cells
isolated from normal or asthmatic donors. Cell culture and characterization
was performed as described previously (17, 26). The cultured cells were all
cytokeratin positive and exhibited a basal cell phenotype, as evidenced by
the expression of cytokeratin 13, irrespective of the type of donor of the
original brushings. Primary cultures were established by seeding freshly
brushed BECs into hormonally supplemented bronchial epithelial growth
medium (Clonetics) containing 50 U/ml penicillin and 50  g/ml strepto-
mycin. At passage two, cells were seeded onto 12-well trays and cultured
until 80% confluent (17) before exposure to RV-16; where indicated, the
caspase 3 inhibitor, ZVD-fmk (120  M; Calbiochem), dexamethasone (10
and 100 nM; Sigma-Aldrich), or human IFN-  (100 IU; Sigma-Aldrich) or
their vehicles were also added to the cells.
Generation and titration of RV. RV-16 and RV-1B stocks were
generated and titrated from infected cultures of Ohio HeLa cells as de-
scribed previously (14). Cells were infected at a multiplicity of infection
of 2. Confirmation of infection and quantification of viral production
was assessed by HeLa titration assay (14) and reverse transcription quanti-
tative polymerase chain reaction (RT-qPCR), as described below. As
negative controls, cells were treated with medium alone and UV inacti-
vated RV-16 (14).
Assessment of cell viability. Viability and apoptosis were assessed by
flow cytometry using AxV conjugated to PE and the vital dye, 7AAD, as
described previously (27). The active forms of caspase 3/7 were detected
using the Apo-One Homogenous Caspase 3/7 assay (Promega). Caspase ac-
tivity was corrected for cell mass determined using methylene blue uptake.
Cell lysis was measured as LDH release into the culture supernatant using
pyruvate as a substrate (Sigma-Aldrich).
RT-qPCR and ELISA. RT-qPCR analysis of IFN-  mRNA and RV-
16 viral RNA (vRNA) gene expression was performed on DNase treated
RNA extracted from BECs using TRIzol (Life Technologies). Total RNA
(1  g) was reverse transcribed using avian myeloblastosis virus transcriptase
(Promega) and random hexamers for IFN-  mRNA and 18S rRNA analy-
sis or oligo (dT)15 for RV-16 vRNA. Real-time detection used an iCy-
clerIQ detection system using a PCR protocol as follows: 42 cycles at 95 C
for 15 s, 60 C for 1 min and 72 C for 15 s. IFN-  signals were normalized to
18S rRNA and relative quantification performed using the   CT method.
Comparisons were made 8 h after infection. Quantification of RV-16 was
achieved using a TAQman assay located in the 5  UTR in conjunction with
the standard curve method. The standard curve was constructed using 10-
fold serial dilutions of RV-16 5  NTR cDNA cloned into PCR 2.1 TOPO
(Invitrogen). Relative values for RV detection were calculated by normaliz-
ing to the starting cell number. Probe: FAM/TAMRA 6-FAMTGAGTC-
CTCCGGCCCCTGAATG, forward primer (RVTM-1) 5 -GTGAAG-
AGCCSCRTGTGCT-3 , reverse primer (RVTM-2) 5 -GCTSCAGGG-
TTAAGGTTAGCC-3 .
ICAM-1 was measured by flow cytometry using a monoclonal anti-
body to ICAM-1 (anti–human CD54; eBioscience) and a FITC-labeled
secondary antibody (DakoCytomation).
IFN-  (Biosource International), IL-6, and RANTES (Biosource In-
ternational) release were measured by ELISA according to the manufac-
turer’s instructions. The sensitivities were  250 pg/ml for IFN- ,  3 pg/
ml for IL-6, and 2 pg/ml for RANTES.
Statistical analysis. When data were normally distributed the mean and
SD have been used, differences between groups have been analyzed using
Student’s t test, when not normally distributed data were analyzed using
nonparametric equivalents and summarized using the median and IQR,
multiple comparisons were first analyzed by the Kruskal Wallis test and thenJEM VOL. 201, March 21, 2005 947
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by individual testing if significant. Correlations were analyzed by Spearman’s
test. A p-value of  0.05 was considered significant.
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